Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Junko Hasegawa-Minato"'
Autor:
Yuki Muroyama, Chihiro Inoue, Fumiyoshi Fujishima, Shogo Shigeta, Junko Hasegawa‐Minato, Muneaki Shimada, Takashi Suzuki
Publikováno v:
Clinical Case Reports, Vol 11, Iss 12, Pp n/a-n/a (2023)
Key Clinical Message Extrapulmonary lymphangioleiomyomatosis (LAM) can present as incidental nodal LAM in gynecological surgery specimens, that warrants systemic investigation and follow‐up of concurrent and subsequent development of pulmonary and
Externí odkaz:
https://doaj.org/article/af3b76fb95784f1ab672052c37efa7ed
Autor:
Tomoka Misawa, Masafumi Toyoshima, Kazuyuki Kitatani, Masumi Ishibashi, Junko Hasegawa-Minato, Shogo Shigeta, Nobuo Yaegashi
Publikováno v:
Cancer Treatment and Research Communications, Vol 27, Iss , Pp 100364- (2021)
Background: Ovarian cancer is the most lethal gynecologic malignancy due to the tumor's acquisition of chemoresistance to platinum-based chemotherapy. To solve this problem, we conducted RNAi-based large-scale screening and determined that tyrosine k
Externí odkaz:
https://doaj.org/article/1417cdda69194f69abc840f1a254a112
Autor:
Mikako Tochigi, Shogo Shigeta, Muneaki Shimada, Shuko Miyahara, Junko Hasegawa-Minato, Yusuke Shibuya, Masumi Ishibashi, Chiaki Hashimoto, Hideki Tokunaga, Nobuo Yaegashi
Publikováno v:
Tohoku Journal of Experimental Medicine; Feb2024, Vol. 262 Issue 2, p85-95, 11p
Autor:
Junko Hasegawa-Minato, Shogo Shigeta, Muneaki Shimada, Masumi Ishibashi, Chiaki Hashimoto, Yusuke Shibuya, Tomoyuki Nagai, Hideki Tokunaga, Hitoshi Niikura, Nobuo Yaegashi
Publikováno v:
Tohoku Journal of Experimental Medicine; Sep2023, Vol. 261 Issue 1, p83-93, 11p
Autor:
Shun, Endo, Shogo, Shigeta, Hideki, Tokunaga, Takanori, Shimizu, Junko, Hasegawa-Minato, Chiaki, Hashimoto, Masumi, Ishibashi, Tomoyuki, Nagai, Naomi, Shiga, Muneaki, Shimada, Nobuo, Yaegashi
Publikováno v:
The Tohoku Journal of Experimental Medicine. 258:1-9
Poly(ADP-ribose) polymerase (PARP) inhibitors theoretically promote synthetic lethality in cancer cells with homologous recombination deficiency (HRD). However, clinical evidence indicates that PARP inhibitors are also effective for treating HRD-nega
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5cfa4b92fa0e6e226bcc1658650fa32
https://doi.org/10.1620/tjem.2022.j050
https://doi.org/10.1620/tjem.2022.j050
Autor:
Masumi Ishibashi, Masafumi Toyoshima, Toshinori Usui, Junko Hasegawa-Minato, Christopher J. Kemp, Xuewei Zhang, Shogo Shigeta, Carla Grandori, Nobuo Yaegashi, Kazuyuki Kitatani
Publikováno v:
Scientific Reports
Scientific Reports, Vol 8, Iss 1, Pp 1-14 (2018)
Scientific Reports, Vol 8, Iss 1, Pp 1-14 (2018)
Platinum resistance is one of the most challenging problems in ovarian cancer treatment. High-throughput functional siRNA screening identified tyrosine kinase with immunoglobulin-like and EGF-like domains 1 (TIE-1) as a gene that confers cells resist
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be84053c9e7426f7f6001b58bb414322
http://hdl.handle.net/10097/00126609
http://hdl.handle.net/10097/00126609
Autor:
Xuewei Zhang, Nobuo Yaegashi, Kazuyuki Kitatani, Junko Hasegawa-Minato, Masafumi Toyoshima, Shogo Shigeta, Carla Grandori, Masumi Ishibashi
Publikováno v:
Oncotarget
c-Myc is a master regulator of various oncogenic functions in many types of human cancers. However, direct c-Myc-targeted therapy has not been successful in the clinic. Here, we explored a novel therapeutic target, which shows synthetic lethality in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::999ce83c2327763d2ee3299e7b83c960
https://pubmed.ncbi.nlm.nih.gov/29423060
https://pubmed.ncbi.nlm.nih.gov/29423060